Asia-pacific Dry Eye Disease Market Forecast 2023-2032

The Asia-Pacific dry eye disease market is set to register a CAGR of 5.60% during the forecast period, 2023-2032. The key growth drivers include the increasing number of ophthalmologists in countries such as India, China, and Japan, in addition to the rising ophthalmic education programs and initiatives for improved eye health.

MARKET INSIGHTS

Australia & New Zealand, India, Japan, Indonesia, China, South Korea, Thailand, and Rest of Asia-Pacific are evaluated for the Asia-Pacific dry eye disease market growth assessment. Dry eye disease (DED) is the most common ocular disease observed in South Korea. As per the research article published in 2019 in the Korean Journal of Family Medicine, female sex, suicidal ideation, a history of cataracts, and hypercholesterolemia are likely to be the risk factors for dry eye symptoms among elderly Koreans. Besides, the country records a rapidly increasing aging population, as well.

On the other hand, as per the survey conducted by Johnson & Johnson Vision in 2019, the majority of people in Thailand, accounting for 77%, frequently suffer from symptoms of Meibomian Gland Dysfunction (MGD) a major cause for dry eye disease. However, while 79% of Thais are not familiar with MGD, 69% choose not to seek medical and professional help, thus, risking their eyesight. Hence, these factors are expected to fuel the dry eye disease market growth in the Asia-Pacific over the forecasting years.

COMPETITIVE INSIGHTS

Key companies operating in the market are Otsuka Holdings Co Ltd, Santen Pharmaceutical Co Ltd, Novartis AG, Sun Pharmaceutical Industries Ltd, etc.

Our report offerings include:

Explore key findings of the overall market
Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
Market Segmentation caters to a thorough assessment of key segments with their market estimations
Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
Key analytics: Porter's Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments

Product Code: 39631

1. RESEARCH SCOPE & METHODOLOGY

1.1. STUDY OBJECTIVES
1.2. METHODOLOGY
1.3. ASSUMPTIONS & LIMITATIONS

2. EXECUTIVE SUMMARY

2.1. MARKET SIZE & ESTIMATES
2.2. MARKET OVERVIEW
2.3. SCOPE OF STUDY
2.4. CRISIS SCENARIO ANALYSIS
2.5. MAJOR MARKET FINDINGS
- 2.5.1. AIR POLLUTION IS A MAJOR CAUSE OF EYE DISEASES
- 2.5.2. COVID-19 CONTRIBUTED TO A HIGH NUMBER OF DRY EYE DISEASE CASES
- 2.5.3. ASIAN RACE IS AT HIGHER RISK OF DEVELOPING DRY EYE DISEASE
- 2.5.4. EXCESSIVE SCREEN TIME CAN INDUCE DRY EYE SYMPTOMS

3. MARKET DYNAMICS

3.1. KEY DRIVERS
- 3.1.1. INTRODUCTION OF NOVEL DIAGNOSTIC TECHNIQUES FOR DRY EYE DISEASE
- 3.1.2. LAUNCH OF PROMISING PIPELINE PRODUCTS FOR DRY EYE DISEASE
- 3.1.3. GROWING INCIDENCE AND PREVALENCE OF DRY EYE AMONG DIFFERENT AGE GROUPS
3.2. KEY RESTRAINTS
- 3.2.1. RISK OF SIDE EFFECTS
- 3.2.2. SUBSTITUTE THERAPIES
- 3.2.3. EXPENSIVE SPECIALTY PRODUCTS AND COMPLEX REIMBURSEMENT SCENARIO

4. KEY ANALYTICS

4.1. PARENT MARKET ANALYSIS
4.2. KEY MARKET TRENDS
4.3. PORTER'S FIVE FORCES ANALYSIS
- 4.3.1. BUYERS POWER
- 4.3.2. SUPPLIERS POWER
- 4.3.3. SUBSTITUTION
- 4.3.4. NEW ENTRANTS
- 4.3.5. INDUSTRY RIVALRY
4.4. GROWTH PROSPECT MAPPING
4.5. MARKET MATURITY ANALYSIS
4.6. MARKET CONCENTRATION ANALYSIS
4.7. VALUE CHAIN ANALYSIS
- 4.7.1. RESEARCH AND DEVELOPMENT
- 4.7.2. MANUFACTURING
- 4.7.3. DISTRIBUTORS
- 4.7.4. POST-SALES MONITORING

5. MARKET BY TYPE

5.1. OTC
5.2. PRESCRIPTION

6. MARKET BY PRODUCT

6.1. ANTI-INFLAMMATORY DRUGS
- 6.1.1. CYCLOSPORINE
- 6.1.2. CORTICOSTEROID
- 6.1.3. OTHER ANTI-INFLAMMATORY DRUGS
6.2. ARTIFICIAL TEARS
6.3. PUNCTAL PLUGS
6.4. SECRETAGOGUES
6.5. OTHER PRODUCTS

7. MARKET BY DISTRIBUTION CHANNEL

7.1. HOSPITAL PHARMACIES
7.2. INDEPENDENT PHARMACIES AND DRUGSTORES
7.3. ONLINE PHARMACIES

8. GEOGRAPHICAL ANALYSIS

8.1. ASIA-PACIFIC
- 8.1.1. MARKET SIZE & ESTIMATES
- 8.1.2. ASIA-PACIFIC DRY EYE DISEASE MARKET DRIVERS
- 8.1.3. ASIA-PACIFIC DRY EYE DISEASE MARKET CHALLENGES
- 8.1.4. ASIA-PACIFIC DRY EYE DISEASE MARKET REGULATORY FRAMEWORK
- 8.1.5. KEY PLAYERS IN ASIA-PACIFIC DRY EYE DISEASE MARKET
- 8.1.6. COUNTRY ANALYSIS
  - 8.1.6.1. CHINA
  - 8.1.6.1.1. CHINA DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES
  - 8.1.6.2. JAPAN
  - 8.1.6.2.1. JAPAN DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES
  - 8.1.6.3. INDIA
  - 8.1.6.3.1. INDIA DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES
  - 8.1.6.4. SOUTH KOREA
  - 8.1.6.4.1. SOUTH KOREA DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES
  - 8.1.6.5. INDONESIA
  - 8.1.6.5.1. INDONESIA DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES
  - 8.1.6.6. THAILAND
  - 8.1.6.6.1. THAILAND DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES
  - 8.1.6.7. AUSTRALIA & NEW ZEALAND
  - 8.1.6.7.1. AUSTRALIA & NEW ZEALAND DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES
  - 8.1.6.8. REST OF ASIA-PACIFIC
  - 8.1.6.8.1. REST OF ASIA-PACIFIC DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES

9. COMPETITIVE LANDSCAPE

9.1. KEY STRATEGIC DEVELOPMENTS
- 9.1.1. MERGERS & ACQUISITIONS
- 9.1.2. PRODUCT LAUNCHES & DEVELOPMENTS
- 9.1.3. PARTNERSHIPS & AGREEMENTS
- 9.1.4. BUSINESS EXPANSIONS & DIVESTITURES
9.2. COMPANY PROFILES
- 9.2.1. AFT PHARMACEUTICALS
- 9.2.2. ALCON
- 9.2.3. ALLERGAN PLC (ACQUIRED BY ABBVIE)
- 9.2.4. BAUSCH HEALTH COMPANIES INC
- 9.2.5. JOHNSON & JOHNSON
- 9.2.6. LUMENIS
- 9.2.7. NOVALIQ GMBH
- 9.2.8. NOVARTIS AG
- 9.2.9. OASIS MEDICAL
- 9.2.10. OTSUKA PHARMACEUTICAL CO LTD
- 9.2.11. SANTEN PHARMACEUTICAL CO LTD
- 9.2.12. SENTISS PHARMA PRIVATE LIMITED
- 9.2.13. SUN PHARMACEUTICAL INDUSTRIES LTD
- 9.2.14. TEVA PHARMACEUTICAL INDUSTRIES LTD
- 9.2.15. VISUFARMA

Product Code: 39631

LIST OF TABLES

TABLE 1: MARKET SNAPSHOT - DRY EYE DISEASE
TABLE 2: ASIA-PACIFIC DRY EYE DISEASE MARKET, BY TYPE, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 3: ASIA-PACIFIC DRY EYE DISEASE MARKET, BY TYPE, FORECAST YEARS, 2023-2032 (IN $ MILLION)
TABLE 4: ASIA-PACIFIC DRY EYE DISEASE MARKET, BY PRODUCT, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 5: ASIA-PACIFIC DRY EYE DISEASE MARKET, BY PRODUCT, FORECAST YEARS, 2023-2032 (IN $ MILLION)
TABLE 6: ASIA-PACIFIC DRY EYE DISEASE MARKET, BY ANTI-INFLAMMATORY DRUGS, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 7: ASIA-PACIFIC DRY EYE DISEASE MARKET, BY ANTI-INFLAMMATORY DRUGS, FORECAST YEARS, 2023-2032 (IN $ MILLION)
TABLE 8: ASIA-PACIFIC DRY EYE DISEASE MARKET, BY DISTRIBUTION CHANNEL, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 9: ASIA-PACIFIC DRY EYE DISEASE MARKET, BY DISTRIBUTION CHANNEL, FORECAST YEARS, 2023-2032 (IN $ MILLION)
TABLE 10: ASIA-PACIFIC DRY EYE DISEASE MARKET, BY COUNTRY, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 11: ASIA-PACIFIC DRY EYE DISEASE MARKET, BY COUNTRY, FORECAST YEARS, 2023-2032 (IN $ MILLION)
TABLE 12: ASIA-PACIFIC DRY EYE DISEASE MARKET REGULATORY FRAMEWORK
TABLE 13: KEY PLAYERS OPERATING IN ASIA-PACIFIC DRY EYE DISEASE MARKET
TABLE 14: LIST OF MERGERS & ACQUISITIONS
TABLE 15: LIST OF PRODUCT LAUNCHES & DEVELOPMENTS
TABLE 16: LIST OF PARTNERSHIPS & AGREEMENTS
TABLE 17: LIST OF BUSINESS EXPANSIONS & DIVESTITURES

LIST OF FIGURES

FIGURE 1: KEY MARKET TRENDS
FIGURE 2: PORTER'S FIVE FORCES ANALYSIS
FIGURE 3: GROWTH PROSPECT MAPPING FOR ASIA-PACIFIC
FIGURE 4: MARKET MATURITY ANALYSIS
FIGURE 5: MARKET CONCENTRATION ANALYSIS
FIGURE 6: VALUE CHAIN ANALYSIS
FIGURE 7: ASIA-PACIFIC DRY EYE DISEASE MARKET, GROWTH POTENTIAL, BY TYPE, IN 2022
FIGURE 8: ASIA-PACIFIC DRY EYE DISEASE MARKET, BY OTC, 2023-2032 (IN $ MILLION)
FIGURE 9: ASIA-PACIFIC DRY EYE DISEASE MARKET, BY PRESCRIPTION, 2023-2032 (IN $ MILLION)
FIGURE 10: ASIA-PACIFIC DRY EYE DISEASE MARKET, GROWTH POTENTIAL, BY PRODUCT, IN 2022
FIGURE 11: ASIA-PACIFIC DRY EYE DISEASE MARKET, BY ANTI-INFLAMMATORY DRUGS, 2023-2032 (IN $ MILLION)
FIGURE 12: ASIA-PACIFIC DRY EYE DISEASE MARKET, GROWTH POTENTIAL, BY ANTI-INFLAMMATORY DRUGS, IN 2022
FIGURE 13: ASIA-PACIFIC DRY EYE DISEASE MARKET, BY CYCLOSPORINE, 2023-2032 (IN $ MILLION)
FIGURE 14: ASIA-PACIFIC DRY EYE DISEASE MARKET, BY CORTICOSTEROID, 2023-2032 (IN $ MILLION)
FIGURE 15: ASIA-PACIFIC DRY EYE DISEASE MARKET, BY OTHER ANTI-INFLAMMATORY DRUGS, 2023-2032 (IN $ MILLION)
FIGURE 16: ASIA-PACIFIC DRY EYE DISEASE MARKET, BY ARTIFICIAL TEARS, 2023-2032 (IN $ MILLION)
FIGURE 17: ASIA-PACIFIC DRY EYE DISEASE MARKET, BY PUNCTAL PLUGS, 2023-2032 (IN $ MILLION)
FIGURE 18: ASIA-PACIFIC DRY EYE DISEASE MARKET, BY SECRETAGOGUES, 2023-2032 (IN $ MILLION)
FIGURE 19: ASIA-PACIFIC DRY EYE DISEASE MARKET, BY OTHER PRODUCTS, 2023-2032 (IN $ MILLION)
FIGURE 20: ASIA-PACIFIC DRY EYE DISEASE MARKET, GROWTH POTENTIAL, BY DISTRIBUTION CHANNEL, IN 2022
FIGURE 21: ASIA-PACIFIC DRY EYE DISEASE MARKET, BY HOSPITAL PHARMACIES, 2023-2032 (IN $ MILLION)
FIGURE 22: ASIA-PACIFIC DRY EYE DISEASE MARKET, BY INDEPENDENT PHARMACIES AND DRUGSTORES, 2023-2032 (IN $ MILLION)
FIGURE 23: ASIA-PACIFIC DRY EYE DISEASE MARKET, BY ONLINE PHARMACIES, 2023-2032 (IN $ MILLION)
FIGURE 24: ASIA-PACIFIC DRY EYE DISEASE MARKET, COUNTRY OUTLOOK, 2022 & 2032 (IN %)
FIGURE 25: CHINA DRY EYE DISEASE MARKET, 2023-2032 (IN $ MILLION)
FIGURE 26: JAPAN DRY EYE DISEASE MARKET, 2023-2032 (IN $ MILLION)
FIGURE 27: INDIA DRY EYE DISEASE MARKET, 2023-2032 (IN $ MILLION)
FIGURE 28: SOUTH KOREA DRY EYE DISEASE MARKET, 2023-2032 (IN $ MILLION)
FIGURE 29: INDONESIA DRY EYE DISEASE MARKET, 2023-2032 (IN $ MILLION)
FIGURE 30: THAILAND DRY EYE DISEASE MARKET, 2023-2032 (IN $ MILLION)
FIGURE 31: VIETNAM DRY EYE DISEASE MARKET, 2023-2032 (IN $ MILLION)
FIGURE 32: AUSTRALIA & NEW ZEALAND DRY EYE DISEASE MARKET, 2023-2032 (IN $ MILLION)
FIGURE 33: REST OF ASIA-PACIFIC DRY EYE DISEASE MARKET, 2023-2032 (IN $ MILLION)